Stockscreener 앱 받기
1.69
24.26%
0.33
전일 마감가:
$1.36
열려 있는:
$1.42
하루 거래량:
4.95M
Relative Volume:
2.62
시가총액:
$154.93M
수익:
-
순이익/손실:
$-217.44M
주가수익비율:
-0.7788
EPS:
-2.17
순현금흐름:
$-205.20M
1주 성능:
+43.22%
1개월 성능:
+27.07%
6개월 성능:
-48.32%
1년 성능:
-75.47%
1일 변동 폭
$1.40
$1.71
1주일 범위
$1.18
$1.71
52주 변동 폭
$1.11
$8.1442
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
PRME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.69 | 154.93M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-20 | 개시 | H.C. Wainwright | Buy |
| 2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-22 | 개시 | Chardan Capital Markets | Buy |
| 2024-04-08 | 개시 | TD Cowen | Buy |
| 2024-04-03 | 개시 | Wedbush | Outperform |
| 2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-10-09 | 개시 | BMO Capital Markets | Outperform |
| 2023-07-31 | 개시 | Guggenheim | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2022-11-14 | 개시 | Goldman | Neutral |
| 2022-11-14 | 개시 | JP Morgan | Overweight |
| 2022-11-14 | 개시 | Jefferies | Buy |
| 2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Prime Medicine Elects Directors at Annual Meeting - TipRanks
Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts - TipRanks
Layoff Tracker: iTeos Winds Down Operations - BioSpace
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Targ - GuruFocus
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus
Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks
Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks
Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks
Prime Medicine Executives Make Bold Stock Purchases! - TipRanks
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Prime Medicine Executives Make Significant Stock Purchases - TradingView
Prime Medicine CEO Acquires 125,000 Shares - TradingView
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN
Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize
CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter
Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus
PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus
Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus
Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus
Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks
Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks
Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa
PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus
Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits - Genetic Engineering and Biotechnology News
Prime Medicine downgraded to Neutral from Overweight at JPMorgan - TipRanks
Prime Medicine to deprioritize CGD programs, reduce headcount by 25% - TipRanks
6 Analysts Assess Prime Medicine: What You Need To Know - Benzinga
CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff - The Boston Globe
Jefferies cuts Prime Medicine stock target to $9, maintains Buy By Investing.com - Investing.com Canada
Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating - marketscreener.com
David Liu gene-editing startup cuts staff, names new CEO - The Business Journals
PRME: Chardan Capital Adjusts Price Target for Prime Medicine | - GuruFocus
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus
Prime Medicine price target lowered to $12 from $16 at Chardan - TipRanks
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish By Stocktwits - Investing.com India
Wedbush Adjusts Prime Medicine Price Target to $8 From $13, Maintains Outperform Rating - marketscreener.com
Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot - BioPharma Dive
Prime Medicine CEO Keith Gottesdiener to step down, Allan Reine to succeed - TipRanks
Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25%Stock Plunges - Nasdaq
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prime Medicine Inc 주식 (PRME) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
1.21%
1.51%
자본화:
|
볼륨(24시간):